Med24
peptide-development 9. 10. 2026 • 2 min read • Medical sciences (Basel, Switzerland)

Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review

Background/objectives Incretin-based therapies, including glucagon like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are increasingly prescribed for obesity, leading to greater recognition of associated dermatological adverse events (AEs). We aimed to...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

A systematic review investigated cutaneous adverse events (AEs) associated with semaglutide, liraglutide, and tirzepatide. The study aimed to characterize the spectrum, frequency, and clinical characteristics of these AEs, focusing on their established use in obesity and diabetes management. A literature search was conducted across MEDLINE, Embase, and Web of Science, including clinical trials, observational studies, pharmacovigilance studies, and case reports. One hundred and one studies were included, detailing skin-related manifestations linked to the three agents. Cutaneous AEs ranged from mild to severe, encompassing injection-site reactions, dysesthesia, and rarer immune-mediated disorders.

Injection-site reactions, particularly erythema, pruritus, and hemorrhage, were most frequently reported with tirzepatide, followed by liraglutide, and less commonly with semaglutide, often dependent on dosage. Dysesthesia was most strongly associated with semaglutide, occurring at approximately 5% with standard doses and up to 20% with high-dose formulations. Other uncommon reactions included angioedema, hypersensitivity reactions, autoimmune blistering diseases, drug eruptions, vasculitis, and severe cutaneous reactions.

Sponsored content

The findings indicate that while most cutaneous AEs are mild and manageable, there are clinically relevant differences in the frequency and nature of these reactions among the three GLP-1 RA agents. Recognition of these common and uncommon skin manifestations may aid in earlier diagnosis, support treatment adherence, and potentially mitigate adverse outcomes.

Original Scientific Source
Medical sciences (Basel, Switzerland)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement